SCHEMBL16631433

SCHEMBL16631433

O=c1[nH]c(Cc2c[nH]nn2)c([C@@H]2O[C@H](CO)C(O)[C@@H]2O)c(=O)[nH]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNP P00491 3/20 0.36
SLC5A2 P31639 2/20 0.36
PAX8 Q06710 1/20 0.35
UMPS P11172 1/20 0.34
PYGL P06737 3/20 0.33
SYNJ2 O15056 1/20 0.33
B4GALT1 P15291 1/20 0.33
P2RY14 Q15391 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GMNN O75496 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
BLM P54132 1/20 0.33
PMP22 Q01453 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
STAT6 P42226 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18080068 0.82 P2RY2 (0.46) B4GALT1P2RY14
SCHEMBL16631410 0.80 SLC5A2 (0.36) PNPSLC5A2PAX8PYGLSYNJ2
SCHEMBL16631276 0.79 SLC5A2 (0.35) PNPSLC5A2
SCHEMBL16631260 0.78 LGALS3 (0.38) PNPSLC5A2
SCHEMBL16631278 0.77 CA1 (0.42)
SCHEMBL16631280 0.76 ADORA3 (0.41) SLC5A2
SCHEMBL30765022 0.74 SYNJ2 (0.38) PNPSLC5A2UMPSSYNJ2KDM4E
SCHEMBL16631473 0.72 ADORA3 (0.35) SLC5A2
SCHEMBL30721680 0.72 UMPS (0.43) PNPUMPSSYNJ2KDM4ELMNA
SCHEMBL16631459 0.72 SYNJ2 (0.36) SLC5A2SYNJ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 PNP 7/4885SLC5A2 3235/4885PAX8 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.